1. Name Of The Medicinal Product
Caverject 5, 10, 20 or 40 micrograms powder for solution for injection
2. Qualitative And Quantitative Composition
Alprostadil 5, 10, 20 or 40 micrograms.
When reconstituted, each 1ml delivers a dose of 5, 10, 20 or 40 micrograms of alprostadil.
For excipients, see section 6.1.
3. Pharmaceutical Form
Powder for Solution for Injection
Powder: A white to off-white powder.
4. Clinical Particulars
4.1 Therapeutic Indications
Caverject is indicated for the treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic or mixed aetiology.
Caverject may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
4.2 Posology And Method Of Administration
Caverject is administered by direct intracavernous injection. A half inch, 27 to 30 gauge needle is generally recommended. The dose of Caverject should be individualised for each patient by careful titration under supervision by a physician.
The intracavernosal injection must be done under sterile conditions. The site of injection is usually along the dorsolateral aspect of the proximal third of the penis. Visible veins should be avoided. Both the side of the penis that is injected and the site of injection must be alternated; prior to the injection, the injection site must be cleansed with an alcohol swab.
To reconstitute Caverject using the prefilled diluent syringe: flip off the plastic cap from the vial, and use one of the swabs to wipe the rubber cap. Fit the 22 gauge needle to the syringe.
Inject the 1 ml of diluent into the vial, and shake to dissolve the powder entirely. Withdraw slightly more than the required dose of Caverject solution, remove the 22 gauge needle, and fit the 30 gauge needle. Adjust volume to the required dose for injection. Following administration, any unused contents of the vial or syringe should be discarded.
A. As an aid to aetiologic diagnosis.
i) Subjects without evidence of neurological dysfunction; 20 micrograms alprostadil to be injected into the corpus cavernosum and massaged through the penis. Should an ensuing erection persist for more than one hour detumescent therapy (please refer to Section 4.9 - Overdose) should be employed prior to the subject leaving the clinic to prevent a risk of priapism.
Over 80% of subjects may be expected to respond to a single 20 micrograms dose of alprostadil. At the time of discharge from the clinic, the erection should have subsided entirely and the penis must be in a completely flaccid state.
ii) Subjects with evidence of neurological dysfunction; these patients can be expected to respond to lower doses of alprostadil. In subjects with erectile dysfunction caused by neurologic disease/trauma the dose for diagnostic testing must not exceed 10 micrograms and an initial dose of 5 micrograms is likely to be appropriate. Should an ensuing erection persist for more than one hour detumescent therapy (please refer to Section 4.9 - Overdose) should be employed prior to the subject leaving the clinic to prevent a risk of priapism. At the time of discharge from the clinic, the erection should have subsided entirely and the penis must be in a completely flaccid state.
B. Treatment
The initial dose of alprostadil in patients with erectile dysfunction of neurogenic origin secondary to spinal cord injury is 1.25 micrograms, with a second dose of 2.5 micrograms, a third of 5 micrograms, and subsequent incremental increases of 5 micrograms until an optimal dose is achieved. For erectile dysfunction of vasculogenic, psychogenic, or mixed aetiology, the initial dose is 2.5 micrograms. The second dose should be 5 micrograms if there is a partial response, and 7.5 micrograms if there is no response. Subsequent incremental increases of 5-10 micrograms should be given until an optimal dose is achieved. If there is no response to the administered dose, then the next higher dose may be given within 1 hour. If there is a response, there should be at least a 1-day interval before the next dose is given. The usual maximum recommended frequency of injection is no more than once daily and no more than three times weekly.
The first injections of alprostadil must be done by medically trained personnel. After proper training and instruction, alprostadil may be injected at home. If self-administration is planned, the physician should make an assessment of the patient's skill and competence with the procedure. It is recommended that patients are regularly monitored (e.g. every 3 months) particularly in the initial stages of self injection therapy when dose adjustments may be needed.
The dose that is selected for self-injection treatment should provide the patient with an erection that is satisfactory for sexual intercourse. It is recommended that the dose administered produces a duration of the erection not exceeding one hour. If the duration is longer, the dose should be reduced. The majority of patients achieve a satisfactory response with doses in the range of 5 to 20 micrograms. Doses of greater than 60 micrograms of alprostadil are not recommended. The lowest effective dose should be used.
4.3 Contraindications
Caverject should not be used in patients who have a known hypersensitivity to any of the constituents of the product; in patients who have conditions that might predispose them to priapism, such as sickle cell anaemia or trait, multiple myeloma, or leukaemia; or in patients with anatomical deformation of the penis, such as angulation, cavernosal fibrosis, or Peyronie's disease. Patients with penile implants should not be treated with Caverject.
Caverject should not be used in men for whom sexual activity is inadvisable or contraindicated.
4.4 Special Warnings And Precautions For Use
Prolonged erection and/or priapism may occur. Patients should be instructed to report to a physician any erection lasting for a prolonged time period, such as 4 hours or longer. Treatment of priapism should not be delayed more than 6 hours (please refer to Section 4.9 - Overdose).
Painful erection is more likely to occur in patients with anatomical deformations of the penis, such as angulation, phimosis, cavernosal fibrosis, Peyronie's disease or plaques. Penile fibrosis, including angulation, fibrotic nodules and Peyronie's disease may occur following the intracavernosal administration of Caverject. The occurrence of fibrosis may increase with increased duration of use. Regular follow-up of patients, with careful examination of the penis, is strongly recommended to detect signs of penile fibrosis or Peyronie's disease. Treatment with Caverject should be discontinued in patients who develop penile angulation, cavernosal fibrosis, or Peyronie's disease.
Patients on anticoagulants such as warfarin or heparin may have increased propensity for bleeding after the intracavernous injection.
Underlying treatable medical causes of erectile dysfunction should be diagnosed and treated prior to initiation of therapy with Caverject.
Use of intracavernosal alprostadil offers no protection from the transmission of sexually transmitted diseases. Individuals who use alprostadil should be counselled about the protective measures that are necessary to guard against the spread of sexually transmitted diseases, including the human immunodeficiency virus (HIV). In some patients, injection of Caverject can induce a small amount of bleeding at the site of injection. In patients infected with blood-born diseases, this could increase the transmission of such diseases to their partner.
Reconstituted solutions of Caverject are intended for single use only, they should be used immediately and not stored.
4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction
No known interactions. Caverject is not intended for co-administration with any other agent for the treatment of erectile dysfunction.
4.6 Pregnancy And Lactation
Not applicable.
(High doses of alprostadil (0.5 to 2.0 mg/kg subcutaneously) had an adverse effect on the reproductive potential of male rats, although this was not seen with lower doses (0.05 to 0.2 mg/kg). Alprostadil did not affect rat spermatogenesis at doses 200 times greater than the proposed human intrapenile dose.
4.7 Effects On Ability To Drive And Use Machines
Not applicable.
4.8 Undesirable Effects
The most frequent adverse reaction after intracavernosal injection of Caverject is penile pain. In studies, 37% of the patients reported penile pain at least once; however, this event was associated with only 11% of the administered injections. In the majority of the cases, penile pain was rated mild or moderate in intensity. 3% of patients discontinued treatment because of penile pain.
Prolonged erection (defined as an erection that lasts for 4 to 6 hours) after intracavernosal administration of Caverject was reported in 4% of patients. The frequency of priapism (defined as an erection that lasts 6 hours or longer) was 0.4%. (Please refer to Section 4.4 - Special warnings and precautions for use). In the majority of cases, spontaneous detumescence occurred.
Penile fibrosis, including angulation, fibrotic nodules and Peyronie's disease was reported in 3% of clinical trial patients overall, however, in one self-injection study in which the duration of use was up to 18 months, the incidence of penile fibrosis was 7.8% (please refer to Section 4.4).
Haematoma and ecchymosis at the site of injection, which is related to the injection technique rather than to the effects of alprostadil, occurred in 3% and 2% of patients, respectively. Penile oedema or rash was reported by 1% of alprostadil treated patients.
The following local adverse reactions were reported by fewer than 1% of patients in clinical studies following intracavernosal injection of Caverject: balanitis, injection site haemorrhage, injection site inflammation, injection site itching, injection site swelling, injection site oedema, urethral bleeding and penile warmth, numbness, yeast infection, irritation, sensitivity, phimosis, pruritus, erythema, venous leak, painful erection and abnormal ejaculation.
In terms of systemic events, 2 to 4% of alprostadil-treated patients reported headache, hypertension, upper respiratory infection, flu-like syndrome, prostatic disorder, localised pain (buttocks pain, leg pain, genital pain, abdominal pain), trauma, and sinusitis. One percent of patients reported each of the following: dizziness, back pain, nasal congestion and cough. The following were reported for less than 1% of patients in clinical trials and were judged to be possibly related to Caverject use: testicular pain, scrotal disorder (redness, pain, spermatocele), scrotal oedema, haematuria, testicular disorder (warmth, swelling, mass, thickening), impaired urination, urinary frequency, urinary urgency, pelvic pain, hypotension, vasodilatation, peripheral vascular disorder, supraventricular extrasystoles, vasovagal reactions, hypaesthesia, non-generalised weakness, diaphoresis, rash, non-application site pruritus, skin neoplasm, nausea, dry mouth, increased serum creatinine, leg cramps and mydriasis.
Haemodynamic changes, manifested as decreases in blood pressure and increases in pulse rate, were observed during clinical studies, principally at doses above 20 micrograms and above 30 micrograms of Caverject, respectively and appeared to be dose-dependent. However, these changes were usually clinically unimportant; only three patients (0.2%) discontinued the treatment because of symptomatic hypotension.
Caverject had no clinically important effect on serum or urine laboratory tests.
4.9 Overdose
The pharmacotoxic signs of alprostadil are similar in all animal species and include depression, soft stools or diarrhoea and rapid breathing. In animals, the lowest acute LD50 was 12 mg/kg which is 12,000 times greater than the maximum recommended human dose of 60 micrograms.
In man, prolonged erection and/or priapism are known to occur following intracavernous administration of vasoactive substances, including alprostadil. Patients should be instructed to report to a physician any erection lasting for a prolonged time period, such as 4 hours or longer.
The treatment of priapism (prolonged erection) should not be delayed more than 6 hours. Initial therapy should be by penile aspiration. Using aseptic technique, insert a 19-21 gauge butterfly needle into the corpus cavernosum and aspirate 20-50 ml of blood. This may detumesce the penis. If necessary, the procedure may be repeated on the opposite side of the penis until a total of up to 100 ml blood has been aspirated. If still unsuccessful, intracavernous injection of alpha-adrenergic medication is recommended. Although the usual contra-indication to intrapenile administration of a vasoconstrictor does not apply in the treatment of priapism, caution is advised when this option is exercised. Blood pressure and pulse should be continuously monitored during the procedure. Extreme caution is required in patients with coronary heart disease, uncontrolled hypertension, cerebral ischaemia, and in subjects taking monoamine oxidase inhibitors. In the latter case, facilities should be available to manage a hypertensive crisis. A 200 microgram/ml solution of phenylephrine should be prepared, and 0.5 to 1.0 ml of the solution injected every 5 to 10 minutes. Alternatively, a 20 microgram/ml solution of adrenaline should be used. If necessary, this may be followed by further aspiration of blood through the same butterfly needle. The maximum dose of phenylephrine should be 1 mg, or adrenaline 100 micrograms (5 ml of the solution). As an alternative metaraminol may be used, but it should be noted that fatal hypertensive crises have been reported. If this still fails to resolve the priapism, urgent surgical referral for further management, which may include a shunt procedure, is required.
5. Pharmacological Properties
5.1 Pharmacodynamic Properties
Alprostadil is present in various mammalian tissues and fluids. It has a diverse pharmacologic profile, among which some of its more important effects are vasodilation, inhibition of platelet aggregation, inhibition of gastric secretion, and stimulation of intestinal and uterine smooth muscle. The pharmacologic effect of alprostadil in the treatment of erectile dysfunction is presumed to be mediated by inhibition of alpha1-adrenergic activity in penile tissue and by its relaxing effect on cavernosal smooth muscle.
5.2 Pharmacokinetic Properties
Following intracavernous injection of 20 micrograms of alprostadil, mean peripheral levels of alprostadil at 30 and 60 minutes after injection are not significantly greater than baseline levels of endogenous PGE1. Peripheral levels of the major circulating metabolite, 15-oxo-13,14-dihydro-PGE1, increase to reach a peak 30 minutes after injection and return to pre-dose levels by 60 minutes after injection. Any alprostadil entering the systemic circulation from the corpus cavernosum will be rapidly metabolized. Following intravenous administration, approximately 80% of the circulating alprostadil is metabolized in one pass through the lungs, primarily by beta- and omega-oxidation. The metabolites are excreted primarily by the kidney and excretion is essentially complete within 24 hours. There is no evidence of tissue retention of alprostadil or its metabolites following intravenous administration.
5.3 Preclinical Safety Data
No relevant information additional to that already contained in this SPC.
6. Pharmaceutical Particulars
6.1 List Of Excipients
Lactose, sodium citrate, hydrochloric acid, sodium hydroxide
6.2 Incompatibilities
Caverject is not intended to be mixed or coadministered with any other products.
6.3 Shelf Life
24 months. Reconstituted solutions should be used immediately and not stored.
40 micrograms only: 24 months under refrigerated conditions (2-8°C). After dispensing, 3 months at room temperature (do not store above 25°C), included in 24 months shelf life. After reconstitution, the product may be stored for 6 hours below 25°C.
6.4 Special Precautions For Storage
Do not store above 25oC. Reconstituted solutions are intended for single use only, they should be used immediately and not stored.
40 micrograms only: Store at 2-8°C until dispensed. After dispensing, may be stored at room temperature (do not store above 25°C) for up to 3 months. After reconstitution, the product may be stored for 6 hours below 25°C. Do not refrigerate or freeze.
6.5 Nature And Contents Of Container
Single pack containing a vial of Caverject 5, 10, 20 or 40 micrograms powder
Packs also each contain a syringe of solvent, a sterile 22G and a 30G needle plus pre-injection swab.
6.6 Special Precautions For Disposal And Other Handling
The presence of benzyl alcohol in the reconstitution vehicle decreases the degree of binding to package surfaces. Therefore, a more consistent product delivery is produced when Bacteriostatic Water for Injection containing benzyl alcohol is used.
5,10 & 20 micrograms only: Use immediately after reconstitution.
7. Marketing Authorisation Holder
Pfizer Limited
Ramsgate Road
Sandwich
Kent, CT13 9NJ
United Kingdom
8. Marketing Authorisation Number(S)
5 mcg PL 00057/0944
10mcg PL 00057/0941
20mcg PL 00057/0942
40mcg PL 00057/0943
9. Date Of First Authorisation/Renewal Of The Authorisation
5 mcg 4 August 2010
10mcg 4 August 2010
20mcg 4 August 2010
40mcg 4 August 2010
10. Date Of Revision Of The Text
27th April 2010
February 2004
11. LEGAL CATEGORY
POM
Ref: CJ2_0UK
No comments:
Post a Comment